Risk of End-Stage Renal Disease in Psoriatic Patients: Real-World Data from a Nationwide Population-Based Cohort Study

Lee, Eun; Han, Ju Hee; Bang, Chul Hwan; Yoo, Seung Ah; Han, Kyung Do; Kim, Hana; Park, Young Min; Lee, Jun Young; Lee, Ji Hyun

doi:10.1038/s41598-019-53017-4

Cited by 19 publications

(24 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional evidence about the role of the Th17/IL-17 axis on Kidney diseases comes from the observation of the increased risk of CKD associated with renal inflammation in human diseases that occur with the hyperactivation of the Th17/IL-17 axis, like psoriasis (210)(211)(212), rheumatoid arthritis (213,214), and ankylosing spondylitis (215)(216)(217). In two studies (in the United Kingdom and Taiwan), psoriasis was associated with an increased risk of chronic kidney disease independent of traditional risk factors (211,212).…”

Section: The Association Between Th17/il-17 Axis Hyperactivity and Several Kidney Diseases (Other Than Lupus Nephritis)mentioning

confidence: 99%

The Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis

Paquissi

Abensur

2021

Front. Med.

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a disease characterized by dysregulation and hyperreactivity of the immune response at various levels, including hyperactivation of effector cell subtypes, autoantibodies production, immune complex formation, and deposition in tissues. The consequences of hyperreactivity to the self are systemic and local inflammation and tissue damage in multiple organs. Lupus nephritis (LN) is one of the most worrying manifestations of SLE, and most patients have this involvement at some point in the course of the disease. Among the effector cells involved, the Th17, a subtype of T helper cells (CD4+), has shown significant hyperactivation and participates in kidney damage and many other organs. Th17 cells have IL-17A and IL-17F as main cytokines with receptors expressed in most renal cells, being involved in the activation of many proinflammatory and profibrotic pathways. The Th17/IL-17 axis promotes and maintains repetitive tissue damage and maladaptive repair; leading to fibrosis, loss of organ architecture and function. In the podocytes, the Th17/IL-17 axis effects include changes of the cytoskeleton with increased motility, decreased expression of health proteins, increased oxidative stress, and activation of the inflammasome and caspases resulting in podocytes apoptosis. In renal tubular epithelial cells, the Th17/IL-17 axis promotes the activation of profibrotic pathways such as increased TGF-β expression and epithelial-mesenchymal transition (EMT) with consequent increase of extracellular matrix proteins. In addition, the IL-17 promotes a proinflammatory environment by stimulating the synthesis of inflammatory cytokines by intrinsic renal cells and immune cells, and the synthesis of growth factors and chemokines, which together result in granulopoiesis/myelopoiesis, and further recruitment of immune cells to the kidney. The purpose of this work is to present the prognostic and immunopathologic role of the Th17/IL-17 axis in Kidney diseases, with a special focus on LN, including its exploration as a potential immunotherapeutic target in this complication.

show abstract

Section: The Association Between Th17/il-17 Axis Hyperactivity and Several Kidney Diseases (Other Than Lupus Nephritis)mentioning

confidence: 99%

The Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis

Paquissi

Abensur

2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“… Indicators of renal impairment are higher in psoriasis patients: urinary albumin excretion rate and microalbuminuria 71,72 Psoriasis patients had a higher risk of developing ESRD ( p < .001) after adjusting for age, gender, household income, region, diabetes, hypertension, and dyslipidemia 73 Duration and severity of psoriasis correlated positively with the ratio of urinary albumin to creatine 74 …”

Section: Resultsmentioning

confidence: 99%

“…Psoriasis patients had a higher risk of developing ESRD ( p < .001) after adjusting for age, gender, household income, region, diabetes, hypertension, and dyslipidemia 73 …”

Section: Resultsmentioning

confidence: 99%

Psoriasis comorbidities and clinical implications when using biologics

Kang

Balogh

Feldman

2021

Dermatological Reviews

View full text Add to dashboard Cite

Background Psoriasis is a cutaneous inflammatory disorder with associated comorbidities which can influence treatment options. Biologics are immune‐modifying agents that can improve or worsen pre‐existing psoriasis comorbidities. The risks associated with a particular biologic agent and its effects on a comorbidity can guide treatment decisions and direct further workup to screen for markers of these comorbidities. Methods A literature search was performed to develop treatment recommendations for psoriasis patients in the background of common comorbidities when considering biologic agents. Results Psoriatic arthritis, inflammatory bowel disease, metabolic syndrome, nonalcoholic fatty liver disease, depression, and malignancies are comorbidities associated with psoriasis that can be affected by certain biologic agents. Conclusion Considerations to make when treating a patient with psoriasis include the severity of disease, the presence of comorbidities, and symptomology that can interact with biologic agents.

show abstract

“…A previous study has shown that proteinuria is significantly associated with psoriasis [ 12 ]. In addition, psoriasis increases the risk of CKD or end-stage renal disease [ 13 , 14 ]. However, whether proteinuria affects the development of psoriasis is unknown.…”

Section: Introductionmentioning

confidence: 99%

Proteinuria and Psoriasis Risk: A Nationwide Population-Based Study

Bae

Kim

Song

et al. 2021

JCM

View full text Add to dashboard Cite

Psoriasis, a chronic inflammatory dermatosis, has been associated with chronic kidney disease or end-stage renal disease. However, the association of the changes or amount of proteinuria with psoriasis development has not been evaluated. Using the Korean National Health Screening database, we assessed psoriasis development until 2018 in 6,576,851 Koreans who underwent health examinations in 2009 and 2011. Psoriasis was defined using the International Classification of Diseases, 10th revision (ICD-10) code L40. The risk of psoriasis was evaluated according to change in proteinuria (never [Neg (no proteinuria)/Neg], new [Neg/Pos (proteinuria present)], past [Pos/Neg] and persistent [Pos/Pos] proteinuria) and the proteinuria amount. During a median 7.23-year follow-up, 162,468 (2.47%) individuals developed psoriasis. After adjustments, the hazard ratio (HR) for psoriasis was higher in the persistent proteinuria group (1.32 [1.24–1.40]) than in the never proteinuria group. The past proteinuria group showed better renal outcome (1.03 [1.00–1.07]) than the new (1.05 [1.01–1.07]) and never proteinuria (reference, 1.00) groups did. The amount of random urine proteinuria was associated with increased HR for psoriasis. Subgroup analyses for age, sex, estimated glomerular filtration rate (eGFR), hypertension and diabetes showed that the persistent proteinuria group had a higher risk of psoriasis than the never proteinuria group, especially at eGFR < 60 mL/min/1.73 m2. Persistent proteinuria is associated with psoriasis risk, and the proteinuria amount significantly affects psoriasis development.

show abstract

Risk of End-Stage Renal Disease in Psoriatic Patients: Real-World Data from a Nationwide Population-Based Cohort Study

Cited by 19 publications

References 36 publications

The Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis

The Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis

Psoriasis comorbidities and clinical implications when using biologics

Proteinuria and Psoriasis Risk: A Nationwide Population-Based Study

Contact Info

Product

Resources

About